It's been quite a month in the legal marijuana industry, and that's just the beginning for one of the best marijuana stocks on the market…
It's a Canadian company at the center of the cannabis oil explosion.
And it just got a major new catalyst...
Medical marijuana investing could be very profitable in 2018.
In June, one company is expected to receive U.S. approval to launch a new cannabis product.
Here's everything you need to know...
NEW YORK CITY – With flicks like "Sister Act," "Jumpin' Jack Flash," and "The Associate" (a personal favorite and a film I believe is greatly underrated), comedic actress Whoopi Goldberg has made a career out of making folks laugh.
But in one of those odd ironies of life, Goldberg was serious – even downright somber – during her appearance at a conference here on the last day of last month as she talked about the sorrow felt by the parents of epilepsy-afflicted children.
"I know dozens of families with children with epilepsy. You see your child disappear," she said, referring to what happens after kids are prescribed traditional seizure medications. "But then you find something better… and the seizures go away."
It was here when Goldberg experienced a mood shift – from somber to mad – as she addressed one of the most frustrating and sorrowful catch-22s in medicine today.
I'm talking about the catch-22 that occurs when the solutions to medical maladies are kicked to the curb when our "elected elite" decide to politicize them.
Now, we've addressed this frustrating conundrum here before in the area of chronic pain.
You see, even though chronic pain is a growing, ever more costly problem here in the United States, elected officials in Washington and at the state level have so politicized pain medications that patients with real afflictions are finding it difficult to find treatment programs.
It turns out childhood epilepsy sufferers are in a similar boat; Goldberg sketched out a similar scenario with childhood epilepsy.
She noted that cannabidiol (also known as CBD) – which comes from the marijuana plant but does not have psychoactive effects like tetrahydrocannabinol (THC), the chemical that gets users high – has been used with some success by parents in halting epileptic seizures in their children.
But that success comes with a backlash.
You have successes, Goldberg said, "and then, child services wants to take [the] child away. That is wrong."
The actress didn't let up at all...
What's the next big thing? If you've been following us at Money Morning, you know it's medical and legal marijuana.
In 2018, the market for legal weed and medical marijuana is going to explode.
And it's presenting us with one of the best profit opportunities we'll ever see...
Marijuana stocks are going to become some of the best long-term investments to make.
Legal sales are expected to skyrocket from $10 billion in 2017 to over $24 billion by 2021.
When it comes to investing, there is nothing like identifying a massive change and finding the companies in the best positions to profit from it.
When it comes to biotech, Wall Street tends to overreact. Though there's no reason for it to be there, biotech is in the dog house, and investors have been conditioned to punish the sector and its stocks whenever the opportunity presents itself.
You see, there are three main reasons biotech is down: Wall Street is worried about high and rising drug prices, the impact of a possible trade war on foreign sales, and expiring patents for some older medications.
Over the last several years, for example, I've read a number of Wall Street reports about the so-called "biotech patent cliff." Simply stated, a drug falls off that "cliff" when its patent runs out and it starts facing competition from generics.
And a number of successful drugs out there are rapidly approaching their patent cliffs.
That sounds bad.
But there are good things happening in biotech, as well. In fact, what you don't hear much about is that the industry is about to bust out.
For example, I was thrilled to see a recent report from Clarivant Analytics, a research firm that works closely with industry leaders and top universities, which says a total of 12 compounds being released in 2018 could become blockbusters.
So I went through the data and found one ultimate biotech blockbuster that I think could lead the pack.
North America's legal marijuana market is expected to soar 145%, from $10 billion in 2017 to $24.5 billion by 2021.
With such tremendous profits on the table, we're bring you the best marijuana stock to buy this year – one that can help you profit from this booming industry.
The marijuana sector is still a volatile market, but with California now "fully legal" and Canada headed that way this summer, there are billions on the table; far too much upside for any investor to ignore.
But with such a massive amount of profit potential, it's all too easy for investors to be tempted by the hype and take the "high-risk" route.
That's why the "conservative-aggressive" approach is the one I recommend for getting started: Target low-risk companies – blue chips, in many cases – that are enabling the broader pot stock sector to flourish.
Marijuana investing is one of the biggest profit opportunities we see in 2018.
That's because the cannabis industry is too big to stop, and more states are lining up to legalize medical marijuana.
Here are three of our favorite pot stocks to watch this year...
